STATCenter·
STAT+: New data may cast doubt on competitiveness of Boehringer’s obesity drug
Boehringer Ingelheim’s obesity drug showed promise in cutting liver fat, but it was less impressive at overall weight loss, new data shows.
Read at STAT →
Health · 1 sources covering this
STAT+: New data may cast doubt on competitiveness of Boehringer’s obesity drug
Boehringer Ingelheim’s obesity drug showed promise in cutting liver fat, but it was less impressive at overall weight loss, new data shows.
Coverage spectrum
0 L · 1 C · 0 R
How 1 sources are covering this
Embed this bias spectrum on your site
Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.
<iframe src="https://statesidedaily.com/embed/cluster/86cd8c7e67c5795bb069c46e0ae0e26f3970355e" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="STAT+: New data may cast doubt on competitiveness of Boehringer’s obesity drug"></iframe>
